SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Christian Eichelberg, Walter L Vervenne, Maria De Santis, Ludwig Fischer von Weikersthal, Peter J Goebell, Christian Lerchenmüller, Uwe Zimmermann, Monique M E M Bos, Werner Freier, Silke Schirrmacher-Memmel, Michael Staehler, Sascha Pahernik (Co-author), Maartje Los, Marcus Schenck, Anne Flörcken, Cornelis van Arkel, Kirsten Hauswald, Martin Indorf, Dana Gottstein, Maurice S Michel

    Research output: Contribution to journalOriginal Articlepeer-review

    119 Citations (Web of Science)
    Original languageEnglish
    Pages (from-to)83-47
    JournalEUROPEAN UROLOGY
    Volume68
    Issue number5
    DOIs
    Publication statusPublished - 2015

    Keywords

    • PHASE-III TRIAL
    • ELDERLY-PATIENTS
    • ANTITUMOR-ACTIVITY
    • 2ND-LINE THERAPY
    • INTERFERON-ALPHA
    • POOLED ANALYSIS
    • CARCINOMA
    • TEMSIROLIMUS
    • PROGRESSION
    • STRATEGIES

    Cite this